


Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. COUL-005/04US	SERIAL NO. 09/326,502
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Stewart M. Kroll, et al.	
		FILING DATE June 4, 1999	GROUP 1617



U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE
	P1					


FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	F1	WO 96/34632	07 Nov '96	PCT			

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)	
D1	BENUA et al., "The Relation of Radioiodine Dosimetry to Results and Compilations in the Treatment of Metaphysics Thyroid Cancer," <u>Amer. J. Roentg.</u> , 87(1): 171-182 (1962)
D2	BROWNELL et al., "Absorbed Fractions for Photon Dosimetry," <u>J. Nuclear Medicine</u> , Supp. 1, MIRD Pamphlet No. 3, pp. 28-39
D3	ETTINGER et al., "Phase I-II Study of Isotopic Immunoglobulin Therapy for Primary Liver Cancer," <u>Cancer Treatment Reports</u> , 66(2): 289-297 (1982)
D4	FURHANG et al., "Thyroid Cancer Dosimetry Using Clearance Fitting," <u>The Journal of Nuclear Medicine</u> , 40(1): 131-136 (1999)
D5	KAMINSKI et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-cell Lymphoma," <u>J. Clinical Oncology</u> , 10(11): 1696-1711 (1992)
D6	KAMINSKI et al., "Radioimmunotherapy of B-cell Lymphoma With (131I)Anti-B1 (Anti-CD20) Antibody," <u>The New England Journal of Medicine</u> , 329(7): 459-465 (1993)
D7	KORAL et al., "CT-SPECT Fusion Plus Conjugate Views for Determining Dosimetry in Iodine-131-Monoclonal Antibody Therapy of Lymphoma Patients," <u>The Journal of Nuclear Medicine</u> , 35(10): 1714-1720 (1994)
D8	LETVIN et al., "Use of Radiolabeled Monoclonal Anti-B1 Antibody for B Lymphocyte Imaging in Rhesus Monkeys," <u>Nucl. Med. Biol.</u> , 14(2): 99-105 (1987)
D9	LOEVINGER et al., "A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides," <u>Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine</u> , Pamphlet No. 1, Revised, pp. 3-10 (March 1976)
D10	ORDER, "Monoclonal Antibodies: Potential Role in Radiation Therapy and Oncology," <u>I. J. Radiation Oncology Bio. Phys.</u> , 8: 1193-1201 (1982)
D11	ORDER et al., "Phase I-II Study of Radiolabeled Antibody Integrated in the Treatment of Primary Hepatic Malignancies," <u>I. J. Radiation Oncology Bio. Phys.</u> , 6: 703-710 (1980)

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	February 2, 2001

* EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. COUL-005/04US	SERIAL NO. 09/328,602
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT: Stewart M. Kroll, et al.	
		FILING DATE June 4, 1999	GROUP 1617



	D12	SIEGEL et al., "Bone Marrow Dosimetry and Toxicity for Radioimmunotherapy," <u>Antibody, Immunoconjugates, and Radiopharmaceuticals</u> , 3(4): 213-233 (1990)	12
	D13	SIEGEL et al., "Sacral Scintigraphy for Bone Marrow Dosimetry in Radioimmunotherapy," <u>Nucl. Med. Biol.</u> , 16(6):553-559, 1989	13
	D14	WAHL et al., "Importance of the Terminal Portion of Tumor Time-Activity Curve in Determining Tumor Dosimetry in Radioimmunotherapy," <u>The Journal of Nuclear Medicine</u> , 32(6): 1314-1315 (1991)	14
	D15	WAHL, "Radiolabeled Antibodies: From Research to Clinical Tool," <u>Decisions in Imaging Economics</u> , pp. 28-34	15
	D16	WEINSTEIN et al., "Monoclonal Antibodies in the Lymphatics: Toward the Diagnosis and Therapy of Tumor Metastases," <u>Science</u> , 218: 1334-1337 (1982)	16
	D17	ZASADNY et al., "Standardized Uptake Values of Normal Tissues at PET with 2-[Fluorine-18]-Fluoro-2-deoxy-D-glucose: Variations with Body Weight and a Method for Correction," <u>Radiology</u> , 189(3): 847-850 (1993)	17
	D18	WAHL et al., "Radioimmunotherapy with I-131-Anti-B-1 for Refractory B-Cell Lymphoma: Updated Phase I Study Results," <u>The Journal of Nuclear Medicine</u> , Supplemental, 36(5): 214P, Abstract No. 961 (May 1995)	18
	D19	ZASADNY et al., "Correlation of Dosimetric Parameters with Hematological Toxicity after Radioimmunotherapy of Non-Hodgkin's Lymphoma with I-131 Anti-B1. Utility of a New Parameter: 'Total Body Dose-Lean'," <u>The Journal of Nuclear Medicine</u> , Supplemental, 36(5): 214P, Abstract No. 962 (May 1995)	19
	D20	EARY et al., "Iodine-131-Labeled Anti-CD20 (B1) Antibody Therapy for Released Non-Hodgkin's Lymphomas: Phase II Trial Results," <u>The Journal of Nuclear Medicine</u> , Supplemental, 36(5): 214P, Abstract No. 963 (May 1995)	20
	D21	EARY et al., "Radioimmunotherapy Treatment Planning Based on Radiation Absorbed Dose or Patient Size," <u>The Journal of Nuclear Medicine</u> , Supplemental, 37(5): 43P, Abstract No. 162 (May 1996)	21
	D22	ZASADNY et al., "A Simplified Method for Determining Therapeutic Activity to Administer for Radioimmunotherapy," <u>The Journal of Nuclear Medicine</u> , Supplemental, 37(5): 43P, Abstract No. 163 (May 1996)	22

EXAMINER 	DATE CONSIDERED 2/2/01
--------------	---------------------------


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANT:
Stewart M. Kroll, et al.

FILING DATE
June 4, 1999

GROUP
1617



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AS	P1 4,831,122	16 May '89	Buchsbaum et al.	530	389	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AS	F2 WO 97/42522	13 Nov '97	PCT				

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

AS	D23	Koral et al., "Preliminary Report of Tumor Dosimetry from I-131 SPECT of Previously-Untreated Patients with B-cell Lymphoma," <u>J. Nuclear Medicine</u> , 39(5 Sppl.):112P, (May 1998), Abstract No. 437
AS	D24	Malcom Rowland et al., <u>Clinical Pharmacokinetics</u> , Chap. 15, pp. 218-228, Lea & Febiger, Philadelphia, (1980)
AS	D25	Rommelfanger et al., "Dosimetry of I-131 Anti-B1 (Anti-CD20) Antibody for Non-Hodgkin's Lymphoma: Comparison of Up-front Treatment vs. Chemotherapy-Refractory Patients," <u>J. Nuclear Medicine</u> , 39(5 Sppl.):186P, Abstract No. 840, (May 1998)
AS	D26	Schmidt et al., "Whole-Body Kinetics and Dosimetry of L-3-[¹²³ I]Iodo-Alpha-Methyltyrosine," <u>European J. Nuclear Medicine</u> , 24(9):1162-1166, (September 1997)
AS	D27	Wahl et al., "Dose Escalation in Radioimmunotherapy Based on Projected Whole Body Dose," <u>J. Nuclear Medicine</u> , 35(5 Sppl.):233P, Abstract No. 952, (1994)
AS	D28	Wahl et al., "Patient-Specific Whole-Body Dosimetry: Principles and a Simplified Method for Clinical Implementation," <u>J. Nuclear Medicine</u> , 39(8 Sppl.):14S-20S, (Aug 1998)

EXAMINER

DATE CONSIDERED

4/2/01

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.